DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for benign neonatal seizures — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBenign neonatal seizures maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for benign neonatal seizures is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
sodium voltage-gated channel alpha subunit 2 (SCN2A) — SCN2A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 3beta,14beta,17beta,25rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6J8E · 3.0 Å · ligand (3beta,14beta,17beta,25R)-3-[4-methoxy-3-(methoxymethyl)butoxy]spirost-5-en (9Z9). Experimental structure, not a prediction.
What the evidence adds up to
Benign neonatal seizures are described in the literature as two rare syndromes: benign neonatal convulsions and benign neonatal familial convulsions. A 2000 review states that the prognosis for these two syndromes is relatively good, while the outcome for early myoclonic encephalopathy and early infantile epileptic encephalopathy is catastrophic. The same review notes that the majority of neonatal seizures are acute, reactive events linked to a wide range of etiologic factors, and that these factors—not the seizures themselves—are the main determinants of eventual developmental outcome. It adds that there is no direct human evidence that the occurrence of seizures in the neonate is the main determinant of long-term outcome.
A 2009 review states that neonatal seizures are common and frequently indicate serious underlying brain injury. It warns that neonatal seizures can permanently disrupt neuronal development, induce synaptic reorganisation, alter plasticity, and prime the brain to increased damage from seizures later in life. Because neonatal seizures predict an increased risk for later epilepsy and other neurological sequelae, the review calls for accurate diagnoses to guide aggressive antiepileptic drug use. A 2015 review lists benign idiopathic neonatal convulsion (fifth day fits) and benign familial neonatal convulsion among the clinical forms recently identified, alongside Ohtahara syndrome and early myoclonic epileptic encephalopathy.
No abstract provides any controlled trial data, response rates, or survival numbers for any drug in benign neonatal seizures. The 2009 review discusses treatment only in general terms, calling for aggressive antiepileptic drug use but offering no specific efficacy results. What is still missing is any randomised trial comparing drugs against placebo or against each other in this specific population, any validated biomarker to stratify benign from catastrophic syndromes at onset, and funding for a prospective study large enough to separate the effect of treatment from the effect of the underlying cause.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Mental Retardation and Developmental Disabilities Research Reviews · 2000 · 82 citations
Neonatal seizures: Early-onset seizure syndromes and their consequences for development
AbstractThe determination of the developmental consequences of seizure syndromes in the neonate is based upon a number of factors which include: understanding of the clinical and electroencephalographic (EEG) features of neonatal seizures; current theories of the mechanisms by which neonatal seizures are generated; a current classification of neonatal seizures; potential etiologic and risk factors for seizures; and therapies. In addition, different seizure types, mechanisms of generation and etiologies of cerebral dysfunction may vary with conceptional age of the infant. There are a few distinct neonatal epileptic syndromes, which are rare, have been well described: benign neonatal convulsions; benign neonatal familial convulsions; early myoclonic encephalopathy and early infantile epileptic encephalopathy. The prognosis for the first two is relatively good while the outcome for the other two with encephalopathy is catastrophic. However, the majority of neonatal seizures occur as acute, reactive events in association with a wide range of etiologic factors. These etiologic factors, as well as those of the more traditionally defined syndromes, are the main determinants of eventual developmental outcome of neonates who experience seizures. Although experimental data suggests that some epileptic seizures eventually may have physiological, histological, metabolic, or behavioral consequences, there is yet direct evidence in humans to suggest that the occurrence of seizures themselves in the neonate is the main determinant of long-term outcome.
Journal of Pediatric Neurology · 2015 · 5 citations · open access
New trends in neonatal seizures
AbstractSeizures are very frequent in neonatal period. A seizure is an abrupt alteration in neurological function of the newborn and it can be due to many different causes. There are new pathogenetic hypothesis that try to clarify the mechanism of neonatal sizures. Leaving aside new four classical types of neonatal seizures (subtle, clonic, tonic, myoclonic), new clinical forms have been recently identified: benign idiopathic neonatal convulsion (fifth day fist), benign familial neonatal convulsion, early epileptic encephalopathy with suppression burst (Ohtahara syndrome); early myoclonic epileptic encephalopathy. Finally, there are some open issues about the treatment and the prognosis of neonatal seizures. This review summarizes current knowledge regarding pathophysiology, treatment and prognosis of neonatal seizures. (J Pediatr Neurol 2004; 2(4): 191–197).
Korean Journal of Pediatrics · 2009 · 0 citations · open access
Treatment and prognosis of neonatal seizures
AbstractSeizures in the neonatal period are common and frequently indicate serious underlying brain injury. Neonatal seizures continue to present a diagnostic and therapeutic challenge to pediatricians because recognition and classification of neonatal seizures remain problematic, particularly when clinicians rely only on clinical criteria. Neonatal seizures can permanently disrupt neuronal development, induce synaptic reorganization, alter plasticity, and 'prime' the brain to increased damage from seizures later in life. Since neonatal seizures predict an increased risk for later epilepsy and other neurological sequelae, accurate diagnoses are needed for aggressive antiepileptic drug use. The present review summarizes the treatment and prognosis of neonatal seizures.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
